methylcobalamin and semaglutide together + Semaglutide / Cyanocobalamin Injection |

A non-randomized control trial

Wegovy pills follow the same prescribing guidelines as other GLP-1 medications

Check out our semaglutide meal plan

Cognitive Decline and Neurodegenerative Conditions Cognitive decline and neurodegenerative conditions show substantial preclinical evidence across multiple pathologies: Stroke models: BPC-157 given during reperfusion counteracted neuronal damage and produced full functional recovery in spatial memory, motor coordination, and balance tests Parkinsons models: MPTP-induced models showed reduced motor symptoms (tremor, rigidity, akinesia), protection of nigrostriatal dopaminergic neurons, and near-complete prevention of mortality Multiple sclerosis models: Cuprizone-induced demyelination resulted in significantly less brain damage and reduced clinical abnormalities when BPC-157 was given in drinking water or intragastrically Traumatic brain injury: Falling weight model studies demonstrated reduced hemorrhage, decreased brain lacerations and edema, and improved early outcomes These diverse models share common mechanisms

Conclusions The study findings confirm that GLP-1 augments VAT metabolism, thereby contributing to its weight reduction effect in individuals

After excluding duplicates and studies that did not meet our inclusion criteria, 7 head to head RCTs were identified [28][30], [32][34], [36] and 4 RCTs were included in the meta-analysis [30], [32], [34], [36] (Figure 1)